2027 ICD-10-CM Diagnosis Code D35.2Benign neoplasm of pituitary gland
ICD-10-CM Codes›C00–D49›D10-D36›D35
- Billable — Valid for Submission
- Risk Adjusts — HCC 23
- Not Chronic
D35.2 is a billable ICD-10-CM diagnosis code for benign neoplasm of pituitary gland. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 643 through 645. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Benign neoplasms.
For Medicare Advantage risk adjustment, D35.2 maps to CMS-HCC Category 23 (Prostate, Breast, and Other Cancers and Tumors) under the V28 model, adding a risk factor of about 0.186 for a community, non-dual, aged beneficiary in payment year 2027.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
D35.2 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.
Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- ACTH-dependent Cushing's syndrome
- Benign neoplasm of craniopharyngeal duct
- Benign neoplasm of pituitary gland
- Benign neoplasm of pituitary gland and craniopharyngeal duct
- Corticotroph adenoma
- Dermoid cyst of brain
- Epidermoid cyst of brain
- Epidermoid cyst of pituitary gland
- Familial isolated pituitary adenoma
- Functioning pituitary neoplasm
- Functionless pituitary adenoma
- Functionless pituitary neoplasm
- Germ cell neoplasm of brain
- Gonadotroph adenoma
- Granular cell tumor
- Granular cell tumor of neurohypophysis
- Hamartoma of brain
- Hamartoma of hypothalamus
- Hamartoma of pituitary and hypothalamus
- Hypercortisolism due to pituitary adenoma
- Hypopituitarism due to pituitary neoplasm
- Invasive benign pituitary adenoma
- Macroprolactinoma
- Mass of neurohypophysis
- Microprolactinoma
- Mixed-functioning pituitary adenoma
- Neoplasm of craniopharyngeal duct
- Pituitary adenoma
- Pituitary adenoma with extrasellar extension
- Pituitary cyst
- Pituitary dermoid and epidermoid cysts
- Pituitary macroadenoma
- Pituitary macroadenoma with extrasellar extension
- Pituitary mesoadenoma
- Pituitary microadenoma
- Prolactinoma
- Secondary hyperprolactinemia
- Secondary hyperprolactinemia due to prolactin-secreting neoplasm
- Somatomammotropinoma
- Somatotroph adenoma
- Spindle cell oncocytoma of posterior pituitary gland
- Suprasellar extension of pituitary adenoma
- Thyrotoxicosis due to inappropriate TSH secretion
- Thyrotoxicosis due to TSHoma
- Thyrotroph adenoma
- Thyrotropin overproduction
Instructional NotesGuidance
Instructions from the official ICD-10-CM Tabular List that apply to D35.2: its own notes plus those printed at D35 and Chapter 2. A note printed at a category, block or chapter applies to every code under it.
Excludes1
Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.
Use Additional Code
Add a second code, after this one, to fully describe the condition.
- code to identify any functional activity
Notes
General instructions on how these codes are used.
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
Source: CMS ICD-10-CM Tabular List. How to read instructional notes.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
Adenoma See Also: Neoplasm, benign, by site;
unspecified site D35.2
unspecified site D35.2
unspecified site D35.2
unspecified site D35.2
unspecified site D35.2
unspecified site D35.2
unspecified site D35.2
unspecified site D35.2
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Benign Pituitary Gland Neoplasm
a neoplasm that arises from the anterior or posterior lobe of pituitary gland and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.
Table of NeoplasmsClinical
Anatomical sites in the Table of Neoplasms that reference this code family.
| Site | Malig. Primary | Malig. Secondary | Ca in situ | Benign | Uncertain | Unspec. |
|---|---|---|---|---|---|---|
| craniobuccal pouch | C75.2 | C79.89 | D09.3 | D35.2 | D44.3 | D49.7 |
| fossa (of) › pituitary | C75.1 | C79.89 | D09.3 | D35.2 | D44.3 | D49.7 |
| hypophysis | C75.1 | C79.89 | D09.3 | D35.2 | D44.3 | D49.7 |
| intrasellar | C75.1 | C79.89 | D09.3 | D35.2 | D44.3 | D49.7 |
| pituitary (body) (fossa) (gland) (lobe) | C75.1 | C79.89 | D09.3 | D35.2 | D44.3 | D49.7 |
| Rathke's pouch | C75.1 | C79.89 | D09.3 | D35.2 | D44.3 | D49.7 |
| sella turcica | C75.1 | C79.89 | D09.3 | D35.2 | D44.3 | D49.7 |
Patient EducationClinical
Benign Tumors
Tumors are abnormal growths in your body. They can be either benign or malignant. Benign tumors aren't cancer. Malignant ones are. Benign tumors grow only in one place. They cannot spread or invade other parts of your body. Even so, they can be dangerous if they press on vital organs, such as your brain.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert D35.2 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About D35.2Overview
What is the ICD-10 code for benign neoplasm of pituitary gland?
The ICD-10-CM code for benign neoplasm of pituitary gland is D35.2 (sometimes written as D352). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
Is D35.2 (Benign neoplasm of other and unspecified endocrine glands) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report benign neoplasm of pituitary gland on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
What MS-DRG does D35.2 group to?
When benign neoplasm of pituitary gland is the principal diagnosis on an inpatient stay, it groups to MS-DRG 644, 645, 643, with relative weights from 0.7461 to 1.6138 depending on complications. Higher weights mean higher Medicare reimbursement.
Can D35.2 be reported with D13.7?
Not as a rule. The Excludes1 note at D35, which applies to D35.2, lists "benign neoplasm of endocrine pancreas (D13.7)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).
Does D35.2 need an additional code?
When the condition applies, yes. The Use Additional Code note at D35, which applies to D35.2, reads: code to identify any functional activity. The additional code is reported after D35.2.
What HCC is D35.2?
D35.2 (benign neoplasm of pituitary gland) maps to CMS-HCC Category 23 (Prostate, Breast, and Other Cancers and Tumors), commonly written as HCC 23, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 12 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 22.
Does D35.2 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, D35.2 adds a risk adjustment factor of about 0.186 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.186 to 0.237 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, HCC 20, HCC 21, and HCC 22) supersedes it when both are reported. See the full factor table on the HCC 23 category page.
